See what CanVECTOR members are publishing to advance the field of venous thromboembolism
Publications since 2016 that are linked to venous thromboembolism and/or anticoagulant therapy

Publications for Marc Carrier

Updated daily

Back to Member List

#	PubMedId	Deleted	Publication
	36841648	0	Mulder FI, Kraaijpoel N, Carrier M, et al. Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study. J Thromb Haemost. 2023 Jan 11:S1538-7836(23)00031-4. doi: 10.1016/j.jtha.2023.01.003.
	36781052	0	Kahn SR, Matino D, Carrier M, et al. First-Person Call to Attend 2023 Congress. J Thromb Haemost. 2023 Feb 11:S1538-7836(23)00117-4. doi: 10.1016/j.jtha.2023.01.039.
	36775414	0	Alsehly AA, Wang TF, Carrier M. Time to rethink extended thromboprophylaxis after cancer surgery? J Thromb Haemost. 2023 Feb;21(2):198-199. doi: 10.1016/j.jtha.2022.11.015.
	36740040	0	Robin P, Le Pennec R, Eddy M, et al. Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data. J Thromb Haemost. 2023 Feb 3:S1538-7836(23)00084-3. doi: 10.1016/j.jtha.2023.01.030.
	36709677	0	Roberge G, Carrier M. Long VITT: A case report. Thromb Res. 2023 Jan 24;223:78-79. doi: 10.1016/j.thromres.2023.01.017.
	36696208	0	de Winter MA, Uijl A, Buller HR, et al. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis. J Thromb Haemost. 2022 Dec 22:S1538-7836(22)07627-9. doi: 10.1016/j.jtha.2022.11.013.
	36696204	0	Shaw JR, Castellucci LA, Siegal D, et al. DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. J Thromb Haemost. 2023 Mar;21(3):433-452. doi: 10.1016/j.jtha.2022.11.029. Epub 2022 Dec 22.
	36696183	0	Aziz J, Wang TF, Siegal D, et al. Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer. J Thromb Haemost. 2022 Dec 27:S1538-7836(22)18255-3. doi: 10.1016/j.jtha.2022.12.016.
	36648242	0	de Winter MA, Buller HR, Carrier M, et al. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 Jan 17:ehac776. doi: 10.1093/eurheartj/ehac776.
	36626707	0	Li A, La J, May SB, et al. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. J Clin Oncol. 2023 Jan 10:JCO2201542. doi: 10.1200/JCO.22.01542.
	36485108	0	Wang TF, Carrier M. The 5 most frequently asked questions about factor Xa inhibitors. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):515-521. doi: 10.1182/hematology.2022000385.
	36452204	0	Haas S, Farjat AE, Pieper K, et al. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease. TH Open. 2022 Nov 3;6(4):e354-e364. doi: 10.1055/s-0042-1757744. eCollection 2022 Oct.
	36413031	0	Tran A, Fernando SM, Gates RS, et al. Efficacy and Safety of Anti-Xa Guided versus Fixed Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism in Trauma Patients - A Systematic Review and Meta-Analysis. Ann Surg. 2022 Nov 22. doi: 10.1097/SLA.0000000000005754.
	36397933	0	Ivankovic V, McAlpine K, Delic E, et al. Extended-duration thromboprophylaxis for abdominopelvic surgery: Development and evaluation of a risk-stratified patient decision aid to facilitate shared decision making. Res Pract Thromb Haemost. 2022 Nov 14;6(8):e12831. doi: 10.1002/rth2.12831. eCollection 2022 Nov.
	36201366	0	Potere N, Barco S, Mahe I, et al. Awareness of Venous Thromboembolism among Patients with Cancer: Preliminary Findings from a Global Initiative for World Thrombosis Day. J Thromb Haemost. 2022 Oct 6. doi: 10.1111/jth.15902.
	36100263	0	Auer RC, Ott M, Karanicolas P, et al. Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial. BMJ. 2022 Sep 13;378:e071375. doi: 10.1136/bmj-2022-071375.
	36028857	0	Antic D, Milic N, Chatzikonstantinou T, et al. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.
	35716055	0	Thachil J, Carrier M, Lisman T. Anticoagulation in thrombocytopenic patients - time to rethink? J Thromb Haemost. 2022 Jun 18. doi: 10.1111/jth.15789.
	35679460	0	Wells PS, Tritschler T, Khan F, et al. Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. Blood Adv. 2022 Jun 9. pii: 485510. doi: 10.1182/bloodadvances.2022007027.
	35660801	0	Brandt W, Brown C, Wang TF, et al. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. Thromb Res. 2022 May 29;216:8-10. doi: 10.1016/j.thromres.2022.05.014.
	35638475	0	da Costa WL Jr, Guffey D, Oluyomi A, et al. Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. Am J Hematol. 2022 May 31. doi: 10.1002/ajh.26623.
	35635332	0	Sanfilippo KM, Wang TF, Carrier M, et al. Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancy. J Thromb Haemost. 2022 May 18. doi: 10.1111/jth.15759.
	35621286	0	Amenyogbe A, Lemire F, Yachnin D, et al. A survey of physician perception and practices regarding pharmacological thromboprophylaxis during chemotherapy for bladder cancer. Can Urol Assoc J. 2022 May 20. pii: cuaj.7865. doi: 10.5489/cuaj.7865.
	35587536	0	Popov J, Coelho S, Carrier M, et al. Step down to six months of prophylactic-dose low-molecular-weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): a pilot study. J Thromb Haemost. 2022 May 19. doi: 10.1111/jth.15760.
	35581123	0	Garas SN, McAlpine K, Ross J, et al. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer. Urol Oncol. 2022 May 14. pii: S1078-1439(22)00116-8. doi: 10.1016/j.urolonc.2022.04.006.
	35439303	0	Ageno W, Beyer-Westendorf J, Contino L, et al. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Adv. 2022 Apr 19. pii: 484971. doi: 10.1182/bloodadvances.2022007397.
	35436439	0	Carrier M, Le Gal G. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. Ann Intern Med. 2022 Apr;175(4):W43-W44. doi: 10.7326/L22-0038.
	35315874	0	Bradbury CA, Lawler PR, Stanworth SJ, et al. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910.
	35309792	0	Shivji S, Carrier M. Screening for cancer in unprovoked venous thromboembolism. Hemasphere. 2019 Jun 30;3(Suppl). pii: HemaSphere-2019-0011. doi: 10.1097/HS9.0000000000000205. eCollection 2019 Jun.
	35275495	0	Roberge G, Carrier M. Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221086283. doi: 10.1177/10760296221086283.
	35263789	0	Roy DC, Wang TF, Mallick R, et al. GDF-15, hs-TnT and NT proBNP for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy. Thromb Haemost. 2022 Mar 9. doi: 10.1055/a-1792-7720.
	35167861	0	Moores LK, Tritschler T, Brosnahan S, et al. Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report. Chest. 2022 Feb 12. pii: S0012-3692(22)00250-1. doi: 10.1016/j.chest.2022.02.006.
	35124234	0	Wang TF, Mallick R, Carrier M, et al. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. Thromb Res. 2022 Jan 31;211:85-87. doi: 10.1016/j.thromres.2022.01.022.
	35040802	0	Kimpton M, Kumar S, Wells PS, et al. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. CMAJ. 2021 Oct 12;193(40):E1551-E1560. doi: 10.1503/cmaj.210523.
	34940092	0	Carrier M, Blais N, Crowther M, et al. Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. Curr Oncol. 2021 Dec 18;28(6):5434-5451. doi: 10.3390/curroncol28060453.
	34861200	0	Edupuganti S, Li M, Wu Z, et al. Factors associated with inferior vena cava filter placement and retrieval for patients with cancer-associated thrombosis. Am J Med. 2021 Nov 30. pii: S0002-9343(21)00791-9. doi: 10.1016/j.amjmed.2021.11.006.
	34807722	0	Le Gal G, Kovacs MJ, Bertoletti L, et al. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. Ann Intern Med. 2021 Nov 23. doi: 10.7326/M21-2981.
	34753191	0	Khan F, Rahman A, Tritschler T, et al. Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thromb Haemost. 2021 Nov 9. doi: 10.1055/a-1690-8728.
	34742140	0	Nayak AL, Zahrai A, Mallick R, et al. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. Thromb Res. 2021 Oct 26;208:79-82. doi: 10.1016/j.thromres.2021.10.018.
	34715510	0	Li A, Brandt W, Brown C, et al. Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. Thromb Res. 2021 Oct 24;208:58-65. doi: 10.1016/j.thromres.2021.10.012.
	34662498	0	Mulder FI, Bosch FTM, Carrier M, et al. Growth differentiation factor-15 for prediction of bleeding in cancer patients. J Thromb Haemost. 2021 Oct 18. doi: 10.1111/jth.15559.
	34649864	0	Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400.
	34636806	0	Tran A, Fernando SM, Rochwerg B, et al. Prognostic Factors Associated With Development of Venous Thromboembolism in Critically Ill Patients-A Systematic Review and Meta-Analysis. Crit Care Med. 2021 Oct 12. pii: 00003246-900000000-95047. doi: 10.1097/CCM.0000000000005382.
	34572833	0	Wang TF, Khorana AA, Carrier M. Thrombotic Complications Associated with Immune Checkpoint Inhibitors. Cancers (Basel). 2021 Sep 14;13(18). pii: cancers13184606. doi: 10.3390/cancers13184606.
	34535037	0	Mahe I, Agnelli G, Ay C, et al. Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: the API-CAT Study. Thromb Haemost. 2021 Sep 17. doi: 10.1055/a-1647-9896.
	34487616	0	Weitz JI, Farjat AE, Ageno W, et al. Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. J Thromb Haemost. 2021 Sep 6. doi: 10.1111/jth.15520.
	34485812	0	Falanga A, Gal GL, Carrier M, et al. Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives. TH Open. 2021 Aug 31;5(3):e376-e386. doi: 10.1055/s-0041-1736037. eCollection 2021 Jul.
	34455706	0	Bosch FTM, Mulder FI, Huisman MV, et al. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost. 2021 Aug 29. doi: 10.1111/jth.15516.
	34438079	0	McAlpine K, Breau RH, Werlang P, et al. Timing of Perioperative Pharmacologic Thromboprophylaxis Initiation and its Effect on Venous Thromboembolism and Bleeding Outcomes: A Systematic Review and Meta-Analysis. J Am Coll Surg. 2021 Nov;233(5):619-631.e14. doi: 10.1016/j.jamcollsurg.2021.07.687. Epub 2021 Aug 24.
	34419428	0	Fernando SM, Tran A, Cheng W, et al. Venous Thromboembolism Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. Chest. 2021 Aug 19. pii: S0012-3692(21)03688-6. doi: 10.1016/j.chest.2021.08.050.
	34403852	0	Fernando SM, Mathew R, Munshi L, et al. Media portrayals of pulmonary embolism. Thromb Res. 2021 Oct;206:52-54. doi: 10.1016/j.thromres.2021.08.006. Epub 2021 Aug 11.
	34399433	0	Wang TF, Carrier M, Fournier K, et al. Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. Thromb Haemost. 2021 Aug 16. doi: 10.1055/a-1588-9155.
	34387202	0	Tran A, Fernando SM, Carrier M, et al. Efficacy and Safety of Low Molecular Weight Heparin Versus Unfractionated Heparin for Prevention of Venous Thromboembolism in Trauma Patients: A Systematic Review and Meta-Analysis. Ann Surg. 2021 Aug 13. pii: 00000658-900000000-93329. doi: 10.1097/SLA.0000000000005157.
	34351722	0	Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
	34351721	0	Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
	34327825	0	Wang TF, Baumann Kreuziger L, Leader A, et al. Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2021 Aug;19(8):2068-2081. doi: 10.1111/jth.15367.
	34318606	0	Candeloro M, van Es N, Cantor N, et al. Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021 Oct;19(10):2618-2628. doi: 10.1111/jth.15476. Epub 2021 Aug 8.
	34296056	0	Krishnaswamy S, Ageno W, Arabi Y, et al. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost. 2021 Jul 16;5(5):e12532. doi: 10.1002/rth2.12532. eCollection 2021 Jul.
	34272818	0	Swan D, Carrier M, Lisman T, et al. Heparin - Messias or Verschlimmbesserung? J Thromb Haemost. 2021 Oct;19(10):2373-2382. doi: 10.1111/jth.15464. Epub 2021 Jul 29.
	34233107	0	Patriquin CJ, Laroche V, Selby R, et al. Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med. 2021 Aug 26;385(9):857-859. doi: 10.1056/NEJMc2109465. Epub 2021 Jul 7.
	34175749	0	Knoll W, Fergusson N, Ivankovic V, et al. Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature. Thromb Res. 2021 Aug;204:114-122. doi: 10.1016/j.thromres.2021.06.010. Epub 2021 Jun 19.
	34161655	0	Caiano L, Carrier M, Marshall A, et al. Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 Oct;19(10):2468-2479. doi: 10.1111/jth.15435. Epub 2021 Jul 12.
	34114153	0	McCurdy JD, Ellen Kuenzig M, Spruin S, et al. Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. Dig Dis Sci. 2021 Jun 10. pii: 10.1007/s10620-021-07064-5. doi: 10.1007/s10620-021-07064-5.
	34097772	0	Martens KL, Amos CI, Hernandez CR, et al. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol. 2021 Sep 1;96(9):1137-1146. doi: 10.1002/ajh.26268. Epub 2021 Jun 24.
	34027291	0	Ikesaka R, Siegal D, Mallick R, et al. Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. Res Pract Thromb Haemost. 2021 May 5;5(4):e12517. doi: 10.1002/rth2.12517. eCollection 2021 May.
	33857789	0	Ladha D, Mallick R, Wang TF, et al. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. Thromb Res. 2021 Jun;202:151-154. doi: 10.1016/j.thromres.2021.03.013. Epub 2021 Mar 21.
	33832217	0	Caiano LM, Riva N, Carrier M, et al. Treatment of portal vein thrombosis: an updated narrative review. Minerva Med. 2021 Apr 9. pii: S0026-4806.21.07526-1. doi: 10.23736/S0026-4806.21.07526-1.
	33725410	0	Thachil J, Khorana A, Carrier M. Similarities and perspectives on the two C's-Cancer and COVID-19. J Thromb Haemost. 2021 May;19(5):1161-1167. doi: 10.1111/jth.15294. Epub 2021 Mar 31.
	33724705	0	Aziz D, Skeith L, Rodger MA, et al. Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. J Thromb Haemost. 2021 Jun;19(6):1526-1532. doi: 10.1111/jth.15303. Epub 2021 Apr 21.
	33691765	0	Sholzberg M, Tang GH, Negri E, et al. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0.
	33570602	0	Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-974. doi: 10.1182/bloodadvances.2020003442.
	33544284	0	Schaefer JK, Li M, Wu Z, et al. Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. J Thromb Thrombolysis. 2021 Jul;52(1):214-223. doi: 10.1007/s11239-021-02392-9. Epub 2021 Feb 5.
	33529872	0	Becattini C, Cimini LA, Carrier M. Challenging anticoagulation cases: A case of pulmonary embolism shortly after spontaneous brain bleeding. Thromb Res. 2021 Apr;200:41-47. doi: 10.1016/j.thromres.2021.01.016. Epub 2021 Jan 26.
	33444199	0	Baumgartner C, Klok FA, Carrier M, et al. Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: protocol for a multicentre randomised placebo-controlled non-inferiority trial (SAFE-SSPE). BMJ Open. 2020 Nov 19;10(11):e040151. doi: 10.1136/bmjopen-2020-040151.
	33405381	0	Le Gal G, Carrier M, Castellucci LA, et al. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. J Thromb Haemost. 2021 Jan;19(1):297-303. doi: 10.1111/jth.15138.
	33368114	0	Kearon C, Carrier M, Gu CS, et al. Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. Semin Thromb Hemost. 2020 Nov;46(8):977-985. doi: 10.1055/s-0040-1718891. Epub 2020 Dec 23.
	33313465	0	den Exter PL, Kroft LJM, Gonsalves C, et al. Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts. Res Pract Thromb Haemost. 2020 Oct 1;4(8):1251-1261. doi: 10.1002/rth2.12422. eCollection 2020 Nov.
	33253514	0	McAlpine K, Breau R, Carrier M, et al. Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre. Can J Surg. 2020 Nov 30;63(6):E562-E568. doi: 10.1503/cjs.015219.
	33229505	0	Khorana AA, Cohen AT, Carrier M, et al. Prevention of venous thromboembolism in ambulatory patients with cancer. ESMO Open. 2020 Nov;5(6):e000948. doi: 10.1136/esmoopen-2020-000948.
	33174368	0	Chiasakul T, Patell R, Maraveyas A, et al. Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. J Thromb Haemost. 2021 Feb;19(2):489-501. doi: 10.1111/jth.15175. Epub 2020 Dec 3.
	33160115	0	Knoll W, Mallick R, Wells PS, et al. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. Thromb Res. 2021 Jan;197:13-15. doi: 10.1016/j.thromres.2020.10.026. Epub 2020 Nov 1.
	33134784	0	Riva N, Carrier M, Gatt A, et al. Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette-based survey. Res Pract Thromb Haemost. 2020 Sep 11;4(7):1192-1202. doi: 10.1002/rth2.12424. eCollection 2020 Oct.
	33104289	0	Schaefer JK, Li M, Wu Z, et al. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. J Thromb Haemost. 2021 Jan;19(1):212-220. doi: 10.1111/jth.15153. Epub 2020 Nov 21.
	33079379	0	Zhang J, Atalla M, Mallick R, et al. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial. J Thromb Thrombolysis. 2021 Apr;51(3):720-724. doi: 10.1007/s11239-020-02317-y. Epub 2020 Oct 20.
	33065408	0	Shaw JR, Kumar V, Mallick R, et al. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thromb Res. 2020 Dec;196:437-443. doi: 10.1016/j.thromres.2020.09.035. Epub 2020 Oct 8.
	32969580	0	Kumar V, Shaw JR, Key NS, et al. D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. Oncologist. 2020 Dec;25(12):1075-1083. doi: 10.1002/onco.13540. Epub 2020 Oct 12.
	32881337	0	Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020 Sep;18(9):2126-2137. doi: 10.1111/jth.14935.
	32815416	0	Houston BL, Lawler PR, Goligher EC, et al. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials. 2020 Oct;17(5):491-500. doi: 10.1177/1740774520943846. Epub 2020 Aug 20.
	32736776	0	Ilich A, Kumar V, Henderson M, et al. Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. Thromb Res. 2020 Jul;191 Suppl 1:S31-S36. doi: 10.1016/S0049-3848(20)30394-7.
	32726911	0	D'Astous J, Carrier M. Screening for Occult Cancer in Patients with Venous Thromboembolism. J Clin Med. 2020 Jul 27;9(8). pii: jcm9082389. doi: 10.3390/jcm9082389.
	32683148	0	Ripsman D, Fergusson DA, Montroy J, et al. A systematic review on the efficacy and safety of low molecular weight heparin as an anticancer therapeutic in preclinical animal models. Thromb Res. 2020 Nov;195:103-113. doi: 10.1016/j.thromres.2020.07.008. Epub 2020 Jul 8.
	32654348	0	Mulder FI, Carrier M, van Doormaal F, et al. Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. J Thromb Haemost. 2020 Oct;18(10):2622-2628. doi: 10.1111/jth.15001. Epub 2020 Aug 4.
	32645667	0	Shaw JR, Carrier M, Dowlatshahi D, et al. Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes. Thromb Res. 2020 Nov;195:21-28. doi: 10.1016/j.thromres.2020.06.044. Epub 2020 Jul 1.
	32575112	0	Carrier M, Wang TF. Direct oral anticoagulants and cancer-associated VTE: good for all, or just some? Blood. 2020 Aug 6;136(6):669-673. doi: 10.1182/blood.2019004177.
	32574420	0	Xu Y, You D, Krzyzaniak H, et al. Effect of oral anticoagulants on hemostatic and thromboembolic complications in hip fracture: A systematic review and meta-analysis. J Thromb Haemost. 2020 Oct;18(10):2566-2581. doi: 10.1111/jth.14977. Epub 2020 Jul 23.
	32563061	0	Murthy SK, Robertson McCurdy AB, Carrier M, et al. Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. Thromb Res. 2020 Oct;194:26-32. doi: 10.1016/j.thromres.2020.06.005. Epub 2020 Jun 3.
	32511684	0	Hill K, Sucha E, Rhodes E, et al. Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. JAMA Intern Med. 2020 Aug 1;180(8):1052-1060. doi: 10.1001/jamainternmed.2020.1835.
	32506364	0	Chibane S, Gibeau G, Poulin F, et al. Hyperacute multi-organ thromboembolic storm in COVID-19: a case report. J Thromb Thrombolysis. 2021 Jan;51(1):25-28. doi: 10.1007/s11239-020-02173-w.
	32502594	0	Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020 Sep;158(3):1143-1163. doi: 10.1016/j.chest.2020.05.559. Epub 2020 Jun 2.
	32473596	0	Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020 Jul;120(7):1004-1024. doi: 10.1055/s-0040-1713152. Epub 2020 May 30.
	32396939	0	Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020 Sep 17;136(12):1433-1441. doi: 10.1182/blood.2020005819.
	32369854	0	Montroy J, Lalu MM, Auer RC, et al. The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis. Thromb Haemost. 2020 May;120(5):832-846. doi: 10.1055/s-0040-1709712. Epub 2020 May 5.
	32346486	0	Legault K, Blostein M, Carrier M, et al. A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome. Pilot Feasibility Stud. 2020 Apr 25;6:52. doi: 10.1186/s40814-020-00594-1. eCollection 2020.
	32311448	0	Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
	32205598	0	Fernando SM, Mok G, Castellucci LA, et al. Impact of Anticoagulation on Mortality and Resource Utilization Among Critically Ill Patients With Major Bleeding. Crit Care Med. 2020 Apr;48(4):515-524. doi: 10.1097/CCM.0000000000004206.
	32091505	0	Roberge G, Carrier M. How to manage patients with symptomatic subsegmental pulmonary embolism? Pol Arch Intern Med. 2020 Apr 30;130(4):310-316. doi: 10.20452/pamw.15211. Epub 2020 Feb 24.
	32045437	0	Kraaijpoel N, Carrier M, Le Gal G, et al. Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. PLoS One. 2020 Feb 11;15(2):e0228788. doi: 10.1371/journal.pone.0228788. eCollection 2020.
	31999844	0	Li A, Carlson JJ, Kuderer NM, et al. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer. 2020 Apr 15;126(8):1736-1748. doi: 10.1002/cncr.32724. Epub 2020 Jan 30.
	31999063	0	Zwicker JI, Wang TF, DeAngelo DJ, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost. 2020 Feb;18(2):278-284. doi: 10.1111/jth.14671.
	31995204	0	McCurdy JD, Kuenzig ME, Smith G, et al. Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. Inflamm Bowel Dis. 2020 Oct 23;26(11):1761-1768. doi: 10.1093/ibd/izaa002.
	31989095	0	Shaw JR, Zhang T, Le Gal G, et al. Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis. Res Pract Thromb Haemost. 2020 Jan 20;4(1):131-140. doi: 10.1002/rth2.12285. eCollection 2020 Jan.
	31978224	0	Wang TF, Carrier M. How I treat obese patients with oral anticoagulants. Blood. 2020 Mar 19;135(12):904-911. doi: 10.1182/blood.2019003528.
	31899848	0	Galanaud JP, Righini M, Le Collen L, et al. Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study. J Thromb Haemost. 2020 Apr;18(4):857-864. doi: 10.1111/jth.14728. Epub 2020 Feb 11.
	31812027	0	Cantor N, Carrier M, Rodger MA, et al. Predictors of long-term cancer diagnosis after an unprovoked thromboembolic event: A post-hoc analysis of the REVERSE cohort study. Thromb Res. 2020 Jan;185:132-134. doi: 10.1016/j.thromres.2019.11.021. Epub 2019 Nov 22.
	31808858	0	Kimpton M, Carrier M. What's new in the prevention and treatment of cancer-associated thrombosis? Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):158-166. doi: 10.1182/hematology.2019000023.
	31727694	0	Mulder FI, Di Nisio M, Ay C, et al. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J. 2020 Feb 6;55(2). pii: 13993003.01697-2019. doi: 10.1183/13993003.01697-2019. Print 2020 Feb.
	31600806	0	Miranda S, Benhamou Y, Wells P, et al. Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. Thromb Haemost. 2019 Nov;119(11):1886-1887. doi: 10.1055/s-0039-1695769. Epub 2019 Oct 10.
	31582557	0	Stephen MS, Castellucci L, Carrier M, et al. Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. Haematologica. 2020 Jun;105(6):e307-e309. doi: 10.3324/haematol.2019.232884. Epub 2019 Oct 3.
	31420937	0	Li A, Kuderer NM, Garcia DA, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost. 2019 Dec;17(12):2141-2151. doi: 10.1111/jth.14613. Epub 2019 Sep 17.
	31380891	0	Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019 Nov 1;179(11):1469-1478. doi: 10.1001/jamainternmed.2019.2431.
	31377000	0	McAlpine K, Breau RH, Knee C, et al. Venous thromboembolism and transfusion after major abdominopelvic surgery. Surgery. 2019 Dec;166(6):1084-1091. doi: 10.1016/j.surg.2019.05.050. Epub 2019 Jul 31.
	31353841	0	Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019 Oct;17(10):1772-1778. doi: 10.1111/jth.14564. Epub 2019 Jul 28.
	31340984	0	Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363.
	31317483	0	Carrier M, Soff G, Le Gal G. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants. Cancer Treat Res. 2019;179:103-115. doi: 10.1007/978-3-030-20315-3_7.
	31279158	0	Rodger MA, Miranda S, Delluc A, et al. Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next? Thromb Res. 2019 Aug;180:105-109. doi: 10.1016/j.thromres.2019.06.017. Epub 2019 Jun 26.
	31273089	0	Delluc A, Miranda S, Exter PD, et al. Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica. 2020 May;105(5):1436-1442. doi: 10.3324/haematol.2019.222828. Epub 2019 Jul 4.
	31271705	0	Di Nisio M, van Es N, Carrier M, et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 Nov;17(11):1866-1874. doi: 10.1111/jth.14561. Epub 2019 Jul 25.
	31207027	0	Delluc A, Wang TF, Yap ES, et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019 Aug;17(8):1247-1252. doi: 10.1111/jth.14478. Epub 2019 Jun 17.
	31176033	0	Al Rawahi B, Almegren M, Carrier M. The efficacy and safety of anticoagulation in cerebral vein thrombosis: A Systematic review and meta-analysis: Re-Abdulaziz Almulhim, Saad Fallatah, Ivo Abraham. Comparing incomparable with the wrong analytics: anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis. Thrombosis Research Volume 178, June 2019, Pages 110-111. Thromb Res. 2019 Aug;180:28. doi: 10.1016/j.thromres.2019.05.020. Epub 2019 May 30.
	31141645	0	Carrier M, Le Gal G, Wells PS. Preventing Venous Thromboembolism in Patients with Cancer. Reply. N Engl J Med. 2019 May 30;380(22):2181. doi: 10.1056/NEJMc1904003.
	31084649	0	Ho ML, Carrier M. Just the facts: Management of life-threatening bleeding with oral anticoagulant use in the emergency department. CJEM. 2019 Jul;21(4):460-463. doi: 10.1017/cem.2019.345. Epub 2019 May 14.
	31066471	0	McCurdy JD, Israel A, Hasan M, et al. A clinical predictive model for post-hospitalisation venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Jun;49(12):1493-1501. doi: 10.1111/apt.15286. Epub 2019 May 8.
	31038838	0	Shaw JR, Douketis J, Le Gal G, et al. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost. 2019 Jul;17(7):1171-1178. doi: 10.1111/jth.14468. Epub 2019 May 29.
	30925842	0	Kimpton M, Carrier M. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism. Expert Opin Drug Saf. 2019 Apr;18(4):313-320. doi: 10.1080/14740338.2019.1601699. Epub 2019 Apr 8.
	30875491	0	Suleman A, Jarvis V, Hadziomerovic A, et al. Implanted vascular access device related deep vein thrombosis in oncology patients: A prospective cohort study. Thromb Res. 2019 May;177:117-121. doi: 10.1016/j.thromres.2019.02.033. Epub 2019 Mar 6.
	30859370	0	Woodruff S, Lee AYY, Carrier M, et al. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. J Thromb Thrombolysis. 2019 May;47(4):495-504. doi: 10.1007/s11239-019-01833-w.
	30731388	0	Chin-Yee N, Tanuseputro P, Carrier M, et al. Thromboembolic disease in palliative and end-of-life care: A narrative review. Thromb Res. 2019 Mar;175:84-89. doi: 10.1016/j.thromres.2018.12.028. Epub 2019 Jan 3.
	30716777	0	Duffett L, Kearon C, Rodger M, et al. Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thromb Haemost. 2019 Mar;119(3):479-489. doi: 10.1055/s-0039-1677793. Epub 2019 Feb 4.
	30595331	0	Carrier M, Altman AD, Blais N, et al. Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. Am J Surg. 2019 Sep;218(3):537-550. doi: 10.1016/j.amjsurg.2018.11.046. Epub 2018 Dec 16.
	30511879	0	Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4.
	30498046	0	Robin P, Eddy M, Sikora L, et al. Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: protocol for a systematic review and meta-analysis of individual participant data. BMJ Open. 2018 Nov 28;8(11):e023939. doi: 10.1136/bmjopen-2018-023939.
	30478093	0	Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019 Jan 24;133(4):291-298. doi: 10.1182/blood-2018-08-835595. Epub 2018 Nov 26.
	30412622	0	Johnston A, Hsieh SC, Carrier M, et al. A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making. PLoS One. 2018 Nov 9;13(11):e0207410. doi: 10.1371/journal.pone.0207410. eCollection 2018.
	30349884	0	Samuelson Bannow BR, Lee AYY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost. 2018 Jun 19;2(4):664-669. doi: 10.1002/rth2.12111. eCollection 2018 Oct.
	30327391	0	Wang KL, van Es N, Cameron C, et al. Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. Heart. 2019 Apr;105(7):545-552. doi: 10.1136/heartjnl-2018-313617. Epub 2018 Oct 16.
	30317403	0	Peleg M, Michalowski W, Wilk S, et al. Ideating Mobile Health Behavioral Support for Compliance to Therapy for Patients with Chronic Disease: A Case Study of Atrial Fibrillation Management. J Med Syst. 2018 Oct 13;42(11):234. doi: 10.1007/s10916-018-1077-4.
	30268858	0	Robin P, Otten HM, Delluc A, et al. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. Thromb Res. 2018 Nov;171:92-96. doi: 10.1016/j.thromres.2018.09.055. Epub 2018 Sep 23.
	30060256	0	Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001. Epub 2018 Jul 30.
	30056293	0	Al Rawahi B, Almegren M, Carrier M. The efficacy and safety of anticoagulation in cerebral vein thrombosis: A systematic review and meta-analysis. Thromb Res. 2018 Sep;169:135-139. doi: 10.1016/j.thromres.2018.07.023. Epub 2018 Jul 25.
	30046762	0	Ikesaka R, Langlois N, Carrier M, et al. Pilot trials in thrombosis: Purpose and pitfalls. Res Pract Thromb Haemost. 2018 Jun 13;2(3):572-579. doi: 10.1002/rth2.12117. eCollection 2018 Jul.
	30046730	0	Shaw JR, Woodfine JD, Douketis J, et al. Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. Res Pract Thromb Haemost. 2018 Feb 16;2(2):282-290. doi: 10.1002/rth2.12076. eCollection 2018 Apr.
	30046669	0	Khan F, Rahman A, Carrier M. Occult cancer detection in venous thromboembolism: the past, the present, and the future. Res Pract Thromb Haemost. 2017 Jun 16;1(1):9-13. doi: 10.1002/rth2.12007. eCollection 2017 Jul.
	29864787	0	Kraaijpoel N, van Es N, Raskob GE, et al. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jul;118(7):1270-1278. doi: 10.1055/s-0038-1649523. Epub 2018 Jun 4.
	29703487	0	Robin P, Carrier M. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thromb Res. 2018 Apr;164 Suppl 1:S7-S11. doi: 10.1016/j.thromres.2017.12.024.
	29703470	0	Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Thromb Res. 2018 Apr;164 Suppl 1:S124-S129. doi: 10.1016/j.thromres.2018.01.018.
	29680814	0	Le Roux PY, Robin P, Tromeur C, et al. SPECT V/Q for the diagnosis of pulmonary embolism: protocol for a systematic review and meta-analysis of diagnostic accuracy and clinical outcome. BMJ Open. 2018 Apr 21;8(4):e022024. doi: 10.1136/bmjopen-2018-022024.
	29564837	0	Schulman S, Gross PL, Ritchie B, et al. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Thromb Haemost. 2018 May;118(5):842-851. doi: 10.1055/s-0038-1636541. Epub 2018 Mar 21.
	29506866	0	Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019 Jan;173:158-163. doi: 10.1016/j.thromres.2018.02.144. Epub 2018 Mar 2.
	29466159	0	Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med. 2018 Feb 22;378(8):699-707. doi: 10.1056/NEJMoa1712746.
	29353682	0	van Es N, Louzada M, Carrier M, et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: A prospective cohort study. Thromb Res. 2018 Mar;163:41-46. doi: 10.1016/j.thromres.2018.01.009. Epub 2018 Jan 9.
	29324333	0	Shaw JR, Castellucci L, Siegal D, et al. Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. Thromb Res. 2018 Mar;163:19-21. doi: 10.1016/j.thromres.2018.01.008. Epub 2018 Jan 5.
	29310057	0	Skeith L, Carrier M, Shivakumar S, et al. Guiding curriculum development of a national research training program in thrombosis medicine: A needs assessment involving faculty and trainees. Thromb Res. 2018 Feb;162:79-86. doi: 10.1016/j.thromres.2017.12.008. Epub 2017 Dec 13.
	29231094	0	Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.
	29224973	0	Wan T, Rodger M, Zeng W, et al. Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study. Thromb Res. 2018 Feb;162:104-109. doi: 10.1016/j.thromres.2017.11.020. Epub 2017 Dec 8.
	29222246	0	Di Nisio M, Carrier M. Incidental venous thromboembolism: is anticoagulation indicated? Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):121-127. doi: 10.1182/asheducation-2017.1.121.
	29212129	0	Douketis JD, Spyropoulos AC, Anderson JM, et al. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2017 Dec;117(12):2415-2424. doi: 10.1160/TH17-08-0553. Epub 2017 Dec 6.
	28942356	0	Ikesaka RT, Kahn SR, Galanaud JP, et al. The importance of post thrombotic syndrome as an outcome after deep venous thrombosis: A survey of Canadian thrombosis clinicians. Thromb Res. 2017 Nov;159:13-15. doi: 10.1016/j.thromres.2017.09.015. Epub 2017 Sep 15.
	28939565	0	Khan F, Rahman A, Carrier M, et al. Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open. 2017 Sep 21;7(9):16950. doi: 10.1136/bmjopen-2017-016950.
	28828492	0	van Es N, Le Gal G, Otten HM, et al. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data. Ann Intern Med. 2017 Sep 19;167(6):410-417. doi: 10.7326/M17-0868. Epub 2017 Aug 22.
	28710972	0	Baumann Kreuziger L, Jaffray J, Carrier M. Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. Thromb Res. 2017 Sep;157:64-71. doi: 10.1016/j.thromres.2017.07.002. Epub 2017 Jul 4.
	28676535	0	McDiarmid S, Scrivens N, Carrier M, et al. Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study. CMAJ Open. 2017 Jun 30;5(3):E535-E539. doi: 10.9778/cmajo.20170010.
	28624717	0	Al Megren M, De Wit C, Al Qahtani M, et al. Management of venous thromboembolism in patients with glioma. Thromb Res. 2017 Aug;156:105-108. doi: 10.1016/j.thromres.2017.06.010. Epub 2017 Jun 8.
	28601834	0	van Es N, Le Gal G, Otten HM, et al. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open. 2017 Jun 10;7(6):e015562. doi: 10.1136/bmjopen-2016-015562.
	28587726	0	Husseinzadeh H, Carrier M. Occult cancer detection in patients with hemostatic disorder and venous thromboembolism. Thromb Res. 2018 Mar;163:242-245. doi: 10.1016/j.thromres.2017.05.034. Epub 2017 Jun 1.
	28528288	0	Fitzpatrick T, Carrier M, Le Gal G. Cancer, atrial fibrillation, and stroke. Thromb Res. 2017 Jul;155:101-105. doi: 10.1016/j.thromres.2017.05.006. Epub 2017 May 9.
	28330840	0	Khan F, Vaillancourt C, Carrier M. Should we screen extensively for cancer after unprovoked venous thrombosis? BMJ. 2017 Mar 22;356:j1081. doi: 10.1136/bmj.j1081.
	28237891	0	van Es N, Wells PS, Carrier M. Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. Thromb Res. 2017 Apr;152:52-60. doi: 10.1016/j.thromres.2017.02.016. Epub 2017 Feb 20.
	28214280	0	McAlpine K, Breau RH, Mallick R, et al. Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. Urol Oncol. 2017 Jul;35(7):457.e1-457.e8. doi: 10.1016/j.urolonc.2017.01.015. Epub 2017 Feb 15.
	28160670	0	Coyle K, Carrier M, Lazo-Langner A, et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res. 2017 Mar;151:67-71. doi: 10.1016/j.thromres.2017.01.007. Epub 2017 Jan 25.
	28139259	0	Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res. 2017 Mar;151:89-95. doi: 10.1016/j.thromres.2017.01.009. Epub 2017 Jan 26.
	28100960	0	Al Rawahi B, Le Gal G, Auer R, et al. A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients post major abdominal surgery. Thromb J. 2017 Jan 13;15:2. doi: 10.1186/s12959-016-0126-9. eCollection 2017.
	28075424	0	Douketis J, Ageno W, Carrier M, et al. Managing challenging patients with venous thromboembolism: a practical, case-based approach. Pol Arch Intern Med. 2017 Jan 4;127(1):41-46. doi: 10.20452/pamw.3879. Epub 2017 Jan 4.
	28049641	0	Skeith L, Carrier M, Robinson SE, et al. Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood. 2017 Feb 23;129(8):934-939. doi: 10.1182/blood-2016-09-728006. Epub 2017 Jan 3.
	27869512	0	Carrier M, Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol. 2017 Jan;10(1):15-22. doi: 10.1080/17474086.2017.1257935. Epub 2016 Nov 21.
	27836513	0	Righini M, Galanaud JP, Guenneguez H, et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol. 2016 Dec;3(12):e556-e562. doi: 10.1016/S2352-3026(16)30131-4. Epub 2016 Nov 8.
	27822904	0	Angriman F, Vazquez FJ, Roy PM, et al. A new prognostic strategy for adult patients with acute pulmonary embolism eligible for outpatient therapy. J Thromb Thrombolysis. 2017 Apr;43(3):326-332. doi: 10.1007/s11239-016-1451-3.
	27815153	0	Jara-Palomares L, Otero R, Jimenez D, et al. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest. 2017 Mar;151(3):564-571. doi: 10.1016/j.chest.2016.10.025. Epub 2016 Nov 1.
	27294776	0	Castellucci LA, Shaw J, Giulivi A, et al. Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency - The PACER pilot study. Thromb Res. 2016 Aug;144:69-71. doi: 10.1016/j.thromres.2016.05.026. Epub 2016 Jun 2.
	27159419	0	Khan F, Carrier M, Rodger M. Cancer Screening After Unprovoked Venous Thromboembolism: A Teachable Moment. JAMA Intern Med. 2016 Jun 1;176(6):739-40. doi: 10.1001/jamainternmed.2016.1783.
	27067984	0	Gheshmy A, Carrier M. Venous thromboembolism and occult cancer: impact on clinical practice. Thromb Res. 2016 Apr;140 Suppl 1:S8-11. doi: 10.1016/S0049-3848(16)30091-3.
	26958226	0	Michalowski M, Wilk S, Rosu D, et al. Expanding a First-Order Logic Mitigation Framework to Handle Multimorbid Patient Preferences. AMIA Annu Symp Proc. 2015 Nov 5;2015:895-904. eCollection 2015.
	26826501	0	Vazquez FJ, Gonzalez JP, LeGal G, et al. Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. Thromb Res. 2016 Feb;138:1-6. doi: 10.1016/j.thromres.2015.12.013. Epub 2015 Dec 17.
	26817957	0	Ihaddadene R, Corsi DJ, Lazo-Langner A, et al. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism. Blood. 2016 Apr 21;127(16):2035-7. doi: 10.1182/blood-2015-11-682963. Epub 2016 Jan 27.
	26780740	0	Khorana AA, Carrier M, Garcia DA, et al. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1):81-91. doi: 10.1007/s11239-015-1313-4.
	26672849	0	Carrier M. Cancer Screening in Unprovoked Venous Thromboembolism. N Engl J Med. 2015 Dec 17;373(25):2475. doi: 10.1056/NEJMc1511798.
	26603493	0	Delluc A, Carrier M. Catheter-related thrombosis: Unresolved issues. Thromb Res. 2015 Dec;136(6):1055-6. doi: 10.1016/j.thromres.2015.10.027. Epub 2015 Oct 19.
	26568174	0	Ihaddadene R, Carrier M. The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety. Expert Opin Drug Saf. 2016 Jan;15(1):65-74. doi: 10.1517/14740338.2016.1120718. Epub 2015 Dec 5.
	26272305	0	Castellucci LA, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res. 2015 Oct;136(4):727-31. doi: 10.1016/j.thromres.2015.07.007. Epub 2015 Jul 14.
	26271200	0	van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25;114(6):1268-76. doi: 10.1160/TH15-06-0452. Epub 2015 Aug 13.
	26095467	0	Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med. 2015 Aug 20;373(8):697-704. doi: 10.1056/NEJMoa1506623. Epub 2015 Jun 22.
	25966905	0	Schulman S, Carrier M, Lee AY, et al. Perioperative Management of Dabigatran: A Prospective Cohort Study. Circulation. 2015 Jul 21;132(3):167-73. doi: 10.1161/CIRCULATIONAHA.115.015688. Epub 2015 May 12.
	25804250	0	van Gaal S, Carrier M, Rodriguez RA, et al. A survey of the use of empiric novel anticoagulants during investigation of stroke. Can J Neurol Sci. 2015 Mar;42(2):135-7. doi: 10.1017/cjn.2015.14.
	25713501	0	Moretto P, Park J, Rodger M, et al. A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness. Thromb J. 2015 Feb 14;13:10. doi: 10.1186/s12959-015-0040-6. eCollection 2015.
	25491940	0	Delluc A, Le Gal G, Scarvelis D, et al. Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. Thromb Res. 2015 Feb;135(2):298-302. doi: 10.1016/j.thromres.2014.11.020. Epub 2014 Dec 2.